Advertisement

Estrogen-Signaling Pathways in Lung Cancer

  • D. C. Márquez-Garbán
  • R. J. Pietras
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)

Lung cancer (LC) is the most common cause of mortality from malignancy throughout the world, causing an estimated 1.2 million deaths annually (1). In the USA, it constitutes the leading cause of cancer death among men and women, exceeding the combined number of deaths from breast, prostate, and colon cancers. Despite advances in chemotherapy treatments, the five-year survival rate for LC has not significantly increased in the past 25 years, remaining at 15%, as compared with 61% for colon cancer, 86% for breast cancer, and 96% for prostate cancer. Cigarette smoking remains the primary risk factor for LC with 85–90% of all LC patients having smoked cigarettes at some time in their lives. Remaining LC cases occur in nonsmokers, mainly women. Of note, there has been a dramatic increase in the number of LC cases in women mainly as a consequence of increased prevalence of smoking. This phenomenon has been defined as a “full blown epidemic” by the US Surgeon General (2), with a 600% increase in the death rate from 1930 to 1997. Moreover, it is projected that mortality from LC will continue to increase as the at-risk populations increases.

Keywords

Epidermal Growth Factor Receptor Estrogen Receptor Aromatase Inhibitor Natl Cancer Inst Estrogen Receptor Alpha 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mackay J, Eriksen M (2002) The Tobacco Atlas. Geneva, Switzerland.Google Scholar
  2. 2.
    Patel JD, Bach PB, Kris MG (2004) Lung cancer in US women: a contemporary epidemic. JAMA 291(14): 1763–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Henschke CI, Miettinen OS (2004) Women’s susceptibility to tobacco carcinogens. Lung Cancer 43(1): 1–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Zang EA, Wynder EL (1996) Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 88(3–4): 183–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Bach PB et al (2003) Variations in lung cancer risk among smokers. J Natl Cancer Inst 95(6): 470–8.PubMedGoogle Scholar
  6. 6.
    Bain C, et al. (2004) Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96(11): 826–34.PubMedGoogle Scholar
  7. 7.
    Taioli E, Wynder EL (1994) Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86(11): 869–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Stabile LP, et al. (2002) Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62(7): 2141–50.PubMedGoogle Scholar
  9. 9.
    Weinberg OK et al. (2005) Aromatase inhibitors in human lung cancer therapy. Cancer Res 65(24): 11287–91.PubMedCrossRefGoogle Scholar
  10. 10.
    Pietras RJ et al. (2005) Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70(5–7): 372–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Dougherty SM et al. (2006) Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 13(1): 113–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Hershberger PA et al. (2005) Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65(4): 1598–605.PubMedCrossRefGoogle Scholar
  13. 13.
    Siegfried JM (2001) Women and lung cancer: does oestrogen play a role? Lancet Oncol 2(8): 506–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Stabile LP, Siegfried JM (2004) Estrogen receptor pathways in lung cancer. Curr Oncol Rep 6(4): 259–67.PubMedCrossRefGoogle Scholar
  15. 15.
    Tiuriunova AM et al. (1986) Hormonal balance in women with lung cancer and its changes after combined treatment. Vopr Onkol, 1986. 32: 2–30.Google Scholar
  16. 16.
    Pezzi V et al (2003) Profiling transcript levels for steroidogenic enzymes in fetal tissues. J Steroid Biochem Mol Biol. 87(2–3): 181–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Radzikowska E, Glaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol. 13(7): 1087–93.PubMedCrossRefGoogle Scholar
  18. 18.
    Travis WD et al. (1996) United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 77(12): 2464–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Patel JD (2005) Lung cancer in women. J Clin Oncol 23(14): p 3212–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Pasqualini JR et al. (1978) Specific binding of estrogens in different fetal tissues of guinea pig during fetal development. Cancer Res 38(11 Pt 2): 4246–50.PubMedGoogle Scholar
  21. 21.
    Khosla SS, Rooney SA (1979) Stimulation of fetal lung surfactant production by administration of 17beta-estradiol to the maternal rabbit. Am J Obstet Gynecol 133(2): 213–6.PubMedGoogle Scholar
  22. 22.
    Radzikowska E, Langfort R, Giedronowicz D (2002) Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg 8(2): 69–73.PubMedGoogle Scholar
  23. 23.
    Croxtall JD et al. (1994) Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem Pharmacol 47(2): 197–202.PubMedCrossRefGoogle Scholar
  24. 24.
    Caltagirone S et al. (1997) Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol 17(1): 51–9.PubMedGoogle Scholar
  25. 25.
    Omoto Y et al. (2001) Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285(2): 340–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Mollerup S et al. (2002) Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37(2): 153–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Fasco MJ, Hurteau GJ, Spivack SD (2002) Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 188(1–2): 125–40.PubMedCrossRefGoogle Scholar
  28. 28.
    Stabile LP et al (2005) Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65(4): 1459–70.PubMedCrossRefGoogle Scholar
  29. 29.
    Kirsch EA et al. (1999) Estrogen acutely stimulates endothelial nitric oxide synthase in H441 human airway epithelial cells. Am J Respir Cell Mol Biol 20(4): 658–66.PubMedGoogle Scholar
  30. 30.
    Kuiper GG et al. (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93(12): 5925–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Patrone C et al. (2003) Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol 23(23): 8542–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Morani A et al. (2006) Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice. Proc Natl Acad Sci USA 103(18): 7165–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Jensen EV, DeSombre ER (1973) Estrogen-receptor interaction. Science 182(108): 126–34.PubMedCrossRefGoogle Scholar
  34. 34.
    Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240(4854): 889–95.PubMedCrossRefGoogle Scholar
  35. 35.
    Katzenellenbogen BS, Frasor J (2004) Therapeutic targeting in the estrogen receptor hormonal pathway. Semin Oncol 31(1 Suppl 3): 28–38.PubMedCrossRefGoogle Scholar
  36. 36.
    Srivastava S et al. (1999) Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest 104(4): 503–13.PubMedCrossRefGoogle Scholar
  37. 37.
    Marquez DC et al. (2006) Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol 246(1–2): 91–100.PubMedCrossRefGoogle Scholar
  38. 38.
    Marquez DC, Pietras RJ (2001) Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20(39): 5420–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Levin ER (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19(8): 1951–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Marquez DC, Pietras RJ (2002) Membrane-associated estrogen receptors and breast cancer, in The Identities of Membrane Steroid Receptors, C.S. Watson, Editor, Kluwer Academic Publisher, Boston. p. 1–10.Google Scholar
  41. 41.
    Norfleet AM et al. (2000) Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors. Faseb J 14(1): 157–65.PubMedGoogle Scholar
  42. 42.
    Razandi M et al. (1999) Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 13(2): 307–19.PubMedCrossRefGoogle Scholar
  43. 43.
    Curtis SW et al. (1996) Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci USA 93(22): 12626–30.PubMedCrossRefGoogle Scholar
  44. 44.
    Marquez DC et al. (2001) Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 16(2): 73–81.PubMedCrossRefGoogle Scholar
  45. 45.
    Pietras RJ (2003) Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 9(5): 361–73.PubMedCrossRefGoogle Scholar
  46. 46.
    Gruber CJ et al. (2002) Production and actions of estrogens. N Engl J Med 346(5): 340–52.PubMedCrossRefGoogle Scholar
  47. 47.
    Kato S et al. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270(5241): 1491–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Dechering K, Boersma C, Mosselman S (2000) Estrogen receptors alpha and beta: two receptors of a kind? Curr Med Chem 7(5): 561–76.PubMedGoogle Scholar
  49. 49.
    Li L, Haynes MP, Bender JR (2003) Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100(8): 4807–12.PubMedCrossRefGoogle Scholar
  50. 50.
    Acconcia F et al. (2004) S-palmitoylation modulates human estrogen receptor-alpha functions. Biochem Biophys Res Commun 316(3): 878–83.PubMedCrossRefGoogle Scholar
  51. 51.
    Acconcia F et al. (2003) Does palmitoylation target estrogen receptors to plasma membrane caveolae? IUBMB Life 55(1): 33–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Wong CW et al. (2002) Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99(23): 14783–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Song RX et al. (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci USA 101(7): 2076–81.PubMedCrossRefGoogle Scholar
  54. 54.
    Pedram A et al. (2002) Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 277(52): 50768–75.PubMedCrossRefGoogle Scholar
  55. 55.
    Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129–39.PubMedCrossRefGoogle Scholar
  56. 56.
    Paez JG et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497–500.PubMedCrossRefGoogle Scholar
  57. 57.
    Beug H, Graf T (1989) Co-operation between viral oncogenes in avian erythroid and myeloid leukaemia. Eur J Clin Invest 19(6): 491–502.PubMedCrossRefGoogle Scholar
  58. 58.
    Sellers WR, Meyerson M (2005) EGFR gene mutations: a call for global × global views of cancer. J Natl Cancer Inst 97(5): 326–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Pietras R, Marquez D, Chen H-W, Ayala R, Ramos L, Slamon D (2003) Improved antitumor receptor therapy with Herceptin and Faslodez for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res 82(Suppl 1): 12–13.Google Scholar
  60. 60.
    Pietras RJ et al. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10(12): 2435–46.PubMedGoogle Scholar
  61. 61.
    Brodie A, Long B, Lu Q (1998) Aromatase expression in the human breast. Breast Cancer Res Treat 49(Suppl 1): S85–91; discussion S109–19.PubMedCrossRefGoogle Scholar
  62. 62.
    Brodie A (2003) Aromatase inhibitor development and hormone therapy: a perspective. Semin Oncol 30(4 Suppl 14): 12–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36: 203–32.PubMedCrossRefGoogle Scholar
  64. 64.
    Dubey S, Siegfried JM, Traynor AM (2006) Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol 7(5): 416–24.PubMedCrossRefGoogle Scholar
  65. 65.
    Traynor A, Schiller J, Stabile L, Kolesar J, Belani C, Hoang T, Dubey S, Eickhoff J, Marcotte S, Siegfried J (2005) Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC) in ASCO.Google Scholar
  66. 66.
    Morishige WK, Uetake CA (1978) Receptors for androgen and estrogen in the rat lung. Endocrinology 102(6): 1827–37.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • D. C. Márquez-Garbán
    • 1
  • R. J. Pietras
  1. 1.LA Division of Hematology-OncologyUniversity of CaliforniaLos AngelesUSA

Personalised recommendations